RxDoctor Payments Data

Dharamveer Singh, MD

Internal Medicine · Davenport, IANPI 1972703858

Payments from drug & device makers

$1,336in general payments, 2019–2025

Across 66 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$165
  • Idorsia Pharmaceuticals US Inc$141
  • Exact Sciences$137
  • AbbVie$110
  • Boehringer Ingelheim$100
  • Itamar Medical Inc$83
  • plus $600 from 17 others

What the payments were for

  • Food & beverage$1,336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,336 in reported general payments places this provider in the 85th percentile of 583 internal medicine providers in Iowa.

See all internal medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$317,701
Medicare patients
307
Services billed
8,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$122,626
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$94,538
JardianceEmpagliflozin75$91,615
EliquisApixaban58$57,930
JanuviaSitagliptin Phosphate23$32,056
MounjaroTirzepatide28$31,559
XareltoRivaroxaban29$29,796
TradjentaLinagliptin22$24,419
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$21,745
FarxigaDapagliflozin Propanediol13$21,619
ShingrixVaricella-Zoster Ge/As01b/Pf92$20,171
ProliaDenosumab11$18,615
TrulicityDulaglutide17$18,057
LinzessLinaclotide14$15,675
Breo ElliptaFluticasone/Vilanterol25$13,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Breo Ellipta, Arexvy$59$157,283256 claims
Novo NordiskOzempic$77$122,62685 claims
Boehringer IngelheimJardiance, Tradjenta$100$116,03497 claims
Lilly USA, LLCMounjaro, Trulicity$14$49,61645 claims
MerckJanuvia$21$32,05623 claims
AstraZenecaFarxiga, Symbicort$165$27,65931 claims
AmgenProlia$47$18,61511 claims
AbbVieLinzess$110$15,67514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 internal medicine providers in Iowa.

Other internal medicine in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →